Pharmaceutical industry: into can be attacked and retreated can be defended recommended 8 shares

Focus on cell therapy, gene sequencing, medical information, Internet medicine and other emerging fields. Haitong Medicine April Viewpoint: Look at the right direction, grasp the tap In addition, with the entry into the annual report of the high-risk period, performance is very important, attach great importance to the identification of growth Can be described as "in and out, retreat can be guarded" attaches great importance to determining growth The traditional pharmaceutical field is facing the pressure of drug price reduction and tender, but the export of innovative drugs and preparations clearly benefits, the future in the bidding process will be divided, product ladder rich, new products more companies have hope to grow out, Hengrui, is the representative of these areas look in the right direction and grasp the tap In, and the fundamental changes; 2, the path of specialization of mobile medical enterprises, including; 3, the field of biomedicine leading companies, gene sequencing, innovative drug CRO continue to track policy in April Concerned about the investment opportunities of blood products brought about by drug price reform, Hualan continued to recommend, Temple of Heaven, Boya concern, continue to pay attention to the nationwide promotion of nucleic acid blood sieve progress to, such as the cycle reversal or transformation driven by the largest increase, in addition, gene sequencing, personalized medical and other stocks also rose the most March combination continued to outperform the market Haitong Pharma's March 2014 monthly portfolio rose by an average of 19.46%, outperforming the pharmaceutical index by 18.87%, with individual stocks, and Da'an genes risk tips Policy is volatile, the valuation of the plate volatility is large related individual stock research Dongfulong: Pharmaceutical equipment industry 4.0 leader
Dongfulong is the domestic pharmaceutical equipment leader: the company based on the freeze-drying system, in recent years through the "extension of mergers and acquisitions and endogenous research and development", respectively, into the water needle linkage line, distribution system, filling line, purification air conditioning, bio-fermentation tank and other fields, is now the absolute leader of domestic pharmaceutical equipment ; Equipment, engineering has upgrade needs: domestic high-end pharmaceutical equipment, such as high-stability bioreactors and other foreign countries have a certain gap, currently mainly rely on imports ; Given the company's high explosive potential for mobile medical care and numerous new drugs (/devices) in reserve, we gave the company an "overweight" rating for the first time, giving the company a target price of $32 for 6 months, corresponding to 45 times PE in 2016 (equivalent to PEG of about 1 per year in 2016) 　　Major uncertainties Uncertain timing of new drug research and marketing, uncertain progress of mergers and acquisitions and integration, large fluctuations in the prices of chemical RAWmaterials and intermediates, changes in mobile medical policy environment and competitive environment, and acquisition of the proportion of subsequent equity in Chongqing Yad (
Haitong Securities ) (Responsible Editor: DF078)